National Stage of PCT/IN03/00090 Attorney Docket No. H1089/20013 Preliminary Amendment Dated September 27, 2004

REMARKS/ARGUMENTS

By this Amendment, claims 2, 3, 5-7, 10-11, 14-17, 19 and 20 are amended, and claims 1, 4, 8, 9, 12, 13 and 18 remain unchanged. Claims 1 - 20 are pending. An Abstract is attached on a separate sheet. No new matter is added.

This Amendment is submitted to better conform the application to United States practice.

It is respectfully submitted that the application is in good form for initial examination on the merits. Accordingly, prompt and favorable examination on the merits is respectfully requested.

Should the Examiner believe that anything further is desirable in order to place the application in even better condition for initial examination and allowance, the Examiner is invited to contact Applicants' undersigned attorney at the telephone number listed below.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN COHEN & POKOTILOW ATD.

September 27, 2004

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

Robert S. Silver

Registration No. 35,681 Customer No. 03000

(215) 567-2010

Attorneys for Applicants

Abstract:

The present invention relates to two novel crystalline forms and a novel 1,4-dioxane solvate of candesartan cilexetil, to processes for their preparation and to pharmaceutical compositions containing them.